Young-onset head and neck cancer patients with FAT1 germline variants had a shorter overall survival [31]; therefore, restoration of the functional NOTCH1 or FAT1 expression in nonsense mutation NOTCH1 or FAT1 in HSNCC is a key issue in anticancer therapy. This evidence concerns the gene NOTCH1 and head and neck cancer.